Person:
ÖZTÜRK CİVELEK, DİLEK

Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
DİLEK
Last Name
ÖZTÜRK CİVELEK
Name
Email Address
Birth Date

Filters

2017 - 20192
Reset filters

Settings

Has files: true × Start date: 2017 × End date: 2019 ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Association between ABCB1, ABCG2 carrier protein and COX-2 enzyme gene polymorphisms and breast cancer risk in a Turkish population
    (2019-01-01T00:00:00Z) Dilek, Ozturk; Ezgi, Oztas; Halil, Kara; Cihan, Uras; Gul, Ozhan; ÖZTÜRK CİVELEK, DİLEK
    Aim: Breast cancer is the most common cancer and the second leading cause of cancer-related deaths among women. Several genetic and environmental factors are known to be involved in breast cancer pathogenesis, but the exact etiology of this disease is complicated and not completely understood. We aimed to investigate whether the gene polymorphisms of ABCB1 and ABCG2 carrier proteins and COX2 enzyme affect breast cancer risk. Method: ABCG2 C421A (rs2231142), ABCB1 C3435T (rs1045642), COX-2 T8473C (rs5275) and COX-2 G306C (rs5277) were genotyped 104 breast cancer patients and 90 healthy controls using a real-time PCR for breast cancer susceptibility. Results: Patients carrying ABCG2 C421A, the CC genotype, had a higher risk of disease compared with patients carrying any A allele (OR = 3.06; 95% CI = 1.49–6.25, p = 0.0019). The other variants showed no association with breast cancer (p > 0.05). Comparing the pathological parameters with the variants, only, the frequency of C allele of ABCB1 C3435T was significantly lower in the estrogen receptor-a (ERa) (OR = 2.25; 95% CI: 0.75–6.76; p = 0.041) and progesterone receptor (PgR) (OR = 3.67; 95% CI: 1.34–10.03; p = 0.008) positive breast cancer patients. Conclusion: ABCB1 C3435T and ABCG2 C421A might represent a potential risk factor for breast cancer for Turkish women
  • Thumbnail Image
    PublicationOpen Access
    Molecular aspects of circadian pharmacology and relevance for cancer chronotherapy
    (2017-10-17) ÖZTÜRK, Narin; Ozturk, DİLEK; Kavakli, Ibrahim Halil; OKYAR, Alper; ÖZTÜRK CİVELEK, DİLEK
    The circadian timing system (CTS) controls various biological functions in mammals including xenobiotic metabolism and detoxification, immune functions, cell cycle events, apoptosis and angiogenesis. Although the importance of the CTS is well known in the pharmacology of drugs, it is less appreciated at the clinical level. Genome-wide studies highlighted that the majority of drug target genes are controlled by CTS. This suggests that chronotherapeutic approaches should be taken for many drugs to enhance their effectiveness. Currently chronotherapeutic approaches are successfully applied in the treatment of different types of cancers. The chronotherapy approach has improved the tolerability and antitumor efficacy of anticancer drugs both in experimental animals and in cancer patients. Thus, chronobiological studies have been of importance in determining the most appropriate time of administration of anticancer agents to minimize their side effects or toxicity and enhance treatment efficacy, so as to optimize the therapeutic ratio. This review focuses on the underlying mechanisms of the circadian pharmacology i.e., chronopharmacokinetics and chronopharmacodynamics of anticancer agents with the molecular aspects, and provides an overview of chronotherapy in cancer and some of the recent advances in the development of chronopharmaceutics